{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:42Z","timestamp":1790840442760,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuroblastoma is the most common extracranial solid tumor in children. Peptide receptor radionuclide therapy (PRRT) is a treatment modality with great potential, however, the predictive indicators for its efficacy remain unclear. The aim of the study is to evaluate the prognostic utility of quantitative metrics obtained from <jats:sup>18<\/jats:sup>F-AlF-NOTATATE PET\/CT at baseline and post-treatment for predicting response in PRRT in pediatric neuroblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with high-risk neuroblastoma that was either recurrent or resistant to treatment were prospectively enrolled for one or two cycles of <jats:sup>177<\/jats:sup>Lu-PRRT. <jats:sup>18<\/jats:sup>F-AlF-NOTATATE PET\/CT was performed 1\u202fmonth before and after PRRT; some patients underwent mid-treatment scans (7\u202fweeks post-cycle). Treatment response was evaluated using a modified approach combining principles from European Organization for Research and Treatment of Cancer (EORTC) criteria and Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria. Lesions were delineated semiautomatically to obtain maximum standardized uptake value (SUV<jats:sub>max<\/jats:sub>), mean standardized uptake value (SUV<jats:sub>mean<\/jats:sub>), ratio of tumor SUV<jats:sub>max<\/jats:sub> to liver SUV<jats:sub>max<\/jats:sub> (SUV<jats:sub>T\/L<\/jats:sub>), ratio of tumor SUV<jats:sub>max<\/jats:sub> to spleen SUV<jats:sub>max<\/jats:sub> (SUV<jats:sub>T\/S<\/jats:sub>), tumor volume, total lesion activity, and heterogeneity values. Data were analyzed using independent <jats:italic>t<\/jats:italic>-tests or Mann\u2013Whitney U tests. Receiver operating characteristic curves were used to determine the optimal cut-offs for PET parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-two patients (13 boys, 9 girls) were included. Baseline PET revealed significantly lower SUV<jats:sub>T\/S<\/jats:sub>, tumor volume, and total lesion activity in non-progressive lesions (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05); SUV<jats:sub>T\/S<\/jats:sub> predicted efficacy (area under the curve [AUC], 0.588). Interim PET showed significantly lower SUV<jats:sub>max<\/jats:sub>, SUV<jats:sub>mean<\/jats:sub>, SUV<jats:sub>T\/L<\/jats:sub>, and SUV<jats:sub>T\/S<\/jats:sub> in non-progressive lesions (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05); SUV<jats:sub>T\/L<\/jats:sub> predicted efficacy (AUC, 0.740). The SUV<jats:sub>max<\/jats:sub> ratio (interim\/baseline) had the highest predictive accuracy, with a cut-off of 1.25 (AUC, 0.796; sensitivity, 73.03%; specificity, 76.92%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Quantitative baseline and mid-treatment <jats:sup>18<\/jats:sup>F-AlF-NOTATATE PET\/CT-derived parameters possess value in predicting PRRT response. An interim-to-baseline PET-derived lesion SUV<jats:sub>max<\/jats:sub> ratio of \u22641.25 can effectively predict neuroblastoma response to PRRT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1615136","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:10:20Z","timestamp":1756354220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of 18F-AlF-NOTATATE PET\/CT in selecting pediatric neuroblastoma candidates for 177Lu-DOTATATE peptide receptor radionuclide therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuxuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.ejca.2015.07.023","article-title":"Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"51","author":"Zhou","year":"2015","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of177 lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]Octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","article-title":"177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma","volume":"52","author":"Gains","year":"2011","journal-title":"J Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s00259-020-04741-x","article-title":"A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma","volume":"47","author":"Gains","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40658-022-00436-4","article-title":"Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]lu-DOTATATE","volume":"9","author":"Malcolm","year":"2022","journal-title":"EJNMMI Phys"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with68 ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68 Ga-DOTATATE compared with111 in-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J Nucl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?","volume":"95","author":"\u00d6ks\u00fcz","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","article-title":"Quantitative 68 Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177 Lu-DOTATATE","volume":"62","author":"Ortega","year":"2021","journal-title":"J Nucl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","author":"Kratochwil","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/cancers16010200","article-title":"Prediction of 177Lu-DOTATATE therapy outcomes in neuroendocrine tumor patients using semi-automatic tumor delineation on 68Ga-DOTATATE PET\/CT","volume":"16","author":"Lee","year":"2023","journal-title":"Cancers"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","article-title":"68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours","volume":"141","author":"Sharma","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","article-title":"Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy","volume":"20","author":"Huizing","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12885-020-06836-y","article-title":"Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET\/MRI with simultaneous acquisition of apparent diffusion coefficient","volume":"20","author":"Weber","year":"2020","journal-title":"BMC Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/cancers14030592","article-title":"Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET\/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT","volume":"14","author":"Durmo","year":"2022","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers14040984","article-title":"[68Ga]DOTATOC PET\/CT radiomics to predict the response in GEP-NETs undergoing [177Lu]DOTATOC PRRT: the \u201ctheragnomics\u201d concept","volume":"14","author":"Laudicella","year":"2022","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"686235","DOI":"10.3389\/fonc.2021.686235","article-title":"Radiomics-based texture analysis of 68Ga-DOTATATE positron emission tomography and computed tomography images as a prognostic biomarker in adults with neuroendocrine cancers treated with 177Lu-DOTATATE","volume":"11","author":"Atkinson","year":"2021","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-019-04474-6","article-title":"Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two \u2018new kids on the block\u2019 in somatostatin receptor imaging","volume":"46","author":"Goffin","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1007\/s00259-023-06275-4","article-title":"Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?","volume":"50","author":"Ninatti","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","article-title":"18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study","volume":"64","author":"Pauwels","year":"2023","journal-title":"J Nucl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.3390\/molecules27206818","article-title":"Preparation and evaluation of [18F]AlF-NOTA-NOC for PET imaging of neuroendocrine tumors: comparison to [68Ga]Ga-DOTA\/NOTA-NOC","volume":"27","author":"Dam","year":"2022","journal-title":"Molecules"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-021-00797-4","article-title":"Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET\/CT","volume":"11","author":"Hou","year":"2021","journal-title":"EJNMMI Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","article-title":"Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors","volume":"154","author":"Tirosh","year":"2018","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.119.236935","article-title":"Inflammation-based index and68 ga-DOTATOC PET\u2013derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with90 Y-DOTATOC","volume":"61","author":"Pauwels","year":"2020","journal-title":"J Nucl Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","author":"Pinker","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.6004\/jnccn.2024.0040","article-title":"Neuroblastoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Bagatell","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00259-010-1720-x","article-title":"Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine","volume":"38","author":"Kroiss","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/RLU.0000000000003577","article-title":"Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma","volume":"46","author":"Fathpour","year":"2021","journal-title":"Clin Nucl Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.advms.2019.10.002","article-title":"The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors","volume":"65","author":"Malczewska","year":"2020","journal-title":"Adv Med Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/diagnostics10121083","article-title":"The challenge of evaluating response to peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors: the present and the future","volume":"10","author":"Liberini","year":"2020","journal-title":"Diagnostics"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1007\/s00259-021-05359-3","article-title":"Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management","volume":"48","author":"Roll","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1148\/rg.2018170132","article-title":"Updates in diagnosis, management, and treatment of neuroblastoma","volume":"38","author":"Swift","year":"2018","journal-title":"Radiographics"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","article-title":"PRRT: identikit of the perfect patient","volume":"22","author":"Albertelli","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-11-3831","article-title":"Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"929391","DOI":"10.3389\/fendo.2022.929391","article-title":"Potential value of pre- and post-therapy [68Ga]ga-DOTA-TATE PET\/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors","volume":"13","author":"Opali\u0144ska","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90 Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","article-title":"Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy","volume":"21","author":"Werner","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2967\/jnumed.119.228072","article-title":"Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using68 ga-DOTATOC and68 ga-DOTATATE","volume":"61","author":"Ilan","year":"2020","journal-title":"J Nucl Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e0159984","DOI":"10.1371\/journal.pone.0159984","article-title":"Revisiting the robustness of PET-based textural features in the context of multi-centric trials","volume":"11","author":"Bailly","year":"2016","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr Relat Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1615136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:10:21Z","timestamp":1756354221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1615136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":47,"alternative-id":["10.3389\/fmed.2025.1615136"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1615136","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"article-number":"1615136"}}